Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir‐based dual therapy. Bi‐lipid study-Reference-Cited by-同舟云学术

Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir‐based dual therapy. Bi‐lipid study

Published:2022-11-16 Issue: Volume: Page:
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Medicine

Author:

Bendala‐Estrada Alejandro D.¹,Diaz‐Almiron Mariana²,Busca Carmen³,Mican Rafael³,Cadiñanos Julen³,Montes Maria Luisa³^ORCID,Martin‐Carbonero Luz³,Valencia Eulalia³,Montejano Rocío³,Delgado‐Hierro Ana³,Bernardino Jose I.³^ORCID

Affiliation:

1. Internal Medicine Torrejón de Ardoz Universitary Hospital Madrid Spain

2. Biostatistics Unit La Paz Research Institute. IdiPAZ Madrid Spain

3. HIV and infectious diseases Unit La Paz University Hospital, IdiPAZ, CIBER of Infectious Diseases (CIBERINFEC) Madrid Spain

Publisher

Wiley

Subject

General Engineering

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.13432

Reference31 articles.

1. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study;Palella FJ;J Acquir Immune Defic Syndr,2006

2. HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database;Alonso A;J Am Heart Assoc,2019

3. Rate of cardiovascular, renal and bone disease and their major risk factors in HIV‐infected individuals on antiretroviral therapy in Spain;Knobel H;Enferm Infecc Microbiol Clin,2018

4. Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study;Weber R;HIV Med,2012

5. Cardiovascular disease prevention policy in human immunodeficiency virus: recommendations from a modeling study;Smit M;Clin Infect Dis,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV);Clinical Infectious Diseases;2024-04-12

2. Reasons, Efficacy and Safety of Switching to Dolutegravir-Based Regimens Among Virologically Suppressed PLWH: A Retrospective Cohort Study of 96 Weeks;Infection and Drug Resistance;2024-04

3. Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting;Journal of Antimicrobial Chemotherapy;2023-10-24